vs
Side-by-side financial comparison of Prime Medicine, Inc. (PRME) and SOCIETY PASS INCORPORATED. (SOPA). Click either name above to swap in a different company.
SOCIETY PASS INCORPORATED. is the larger business by last-quarter revenue ($1.4M vs $838.0K, roughly 1.6× Prime Medicine, Inc.). SOCIETY PASS INCORPORATED. runs the higher net margin — -370.8% vs -5498.7%, a 5127.8% gap on every dollar of revenue. On growth, SOCIETY PASS INCORPORATED. posted the faster year-over-year revenue change (-17.6% vs -61.6%). SOCIETY PASS INCORPORATED. produced more free cash flow last quarter ($-16.7M vs $-37.5M).
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
The Wilderness Society is an Australian, community-based, not-for-profit non-governmental environmental advocacy organisation.
PRME vs SOPA — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $838.0K | $1.4M |
| Net Profit | $-46.1M | $-5.1M |
| Gross Margin | — | 64.3% |
| Operating Margin | -5800.5% | -379.9% |
| Net Margin | -5498.7% | -370.8% |
| Revenue YoY | -61.6% | -17.6% |
| Net Profit YoY | -9.0% | -271.5% |
| EPS (diluted) | $-0.22 | $-0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $838.0K | — | ||
| Q3 25 | $1.2M | $1.4M | ||
| Q2 25 | $1.1M | $2.5M | ||
| Q1 25 | $1.5M | $1.5M | ||
| Q4 24 | $2.2M | $1.9M | ||
| Q3 24 | — | $1.7M | ||
| Q2 24 | $0 | $1.7M | ||
| Q1 24 | $591.0K | $1.8M |
| Q4 25 | $-46.1M | — | ||
| Q3 25 | $-50.6M | $-5.1M | ||
| Q2 25 | $-52.6M | $479.0K | ||
| Q1 25 | $-51.9M | $-1.8M | ||
| Q4 24 | $-42.3M | $-4.1M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | $-55.3M | $-1.9M | ||
| Q1 24 | $-45.8M | $-2.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | 64.3% | ||
| Q2 25 | — | 56.5% | ||
| Q1 25 | — | 31.6% | ||
| Q4 24 | — | 28.9% | ||
| Q3 24 | — | 21.8% | ||
| Q2 24 | — | 27.1% | ||
| Q1 24 | — | 26.7% |
| Q4 25 | -5800.5% | — | ||
| Q3 25 | -4406.0% | -379.9% | ||
| Q2 25 | -4787.2% | -6.1% | ||
| Q1 25 | -3603.3% | -126.6% | ||
| Q4 24 | -2025.7% | -165.6% | ||
| Q3 24 | — | -70.1% | ||
| Q2 24 | — | -126.0% | ||
| Q1 24 | -8179.5% | -156.6% |
| Q4 25 | -5498.7% | — | ||
| Q3 25 | -4129.1% | -370.8% | ||
| Q2 25 | -4716.7% | 19.1% | ||
| Q1 25 | -3568.8% | -124.9% | ||
| Q4 24 | -1936.6% | -217.5% | ||
| Q3 24 | — | -82.2% | ||
| Q2 24 | — | -113.3% | ||
| Q1 24 | -7743.0% | -153.8% |
| Q4 25 | $-0.22 | — | ||
| Q3 25 | $-0.32 | $-0.89 | ||
| Q2 25 | $-0.41 | $0.10 | ||
| Q1 25 | $-0.40 | $-0.44 | ||
| Q4 24 | $-0.31 | $-1.03 | ||
| Q3 24 | — | $-0.48 | ||
| Q2 24 | $-0.46 | $-0.73 | ||
| Q1 24 | $-0.44 | $-1.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.0M | $6.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $120.9M | $13.9M |
| Total Assets | $342.7M | $32.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.0M | — | ||
| Q3 25 | $71.4M | $6.6M | ||
| Q2 25 | $53.8M | $8.2M | ||
| Q1 25 | $91.9M | $7.1M | ||
| Q4 24 | $182.5M | $7.6M | ||
| Q3 24 | — | $4.2M | ||
| Q2 24 | $55.6M | $833.9K | ||
| Q1 24 | $94.2M | $1.6M |
| Q4 25 | $120.9M | — | ||
| Q3 25 | $161.8M | $13.9M | ||
| Q2 25 | $60.9M | $2.4M | ||
| Q1 25 | $106.9M | $-663.0K | ||
| Q4 24 | $153.1M | $-2.1M | ||
| Q3 24 | — | $862.6K | ||
| Q2 24 | $196.6M | $2.4M | ||
| Q1 24 | $243.8M | $3.5M |
| Q4 25 | $342.7M | — | ||
| Q3 25 | $385.0M | $32.9M | ||
| Q2 25 | $279.0M | $29.2M | ||
| Q1 25 | $328.2M | $22.9M | ||
| Q4 24 | $297.5M | $21.3M | ||
| Q3 24 | — | $17.0M | ||
| Q2 24 | $259.7M | $13.0M | ||
| Q1 24 | $311.4M | $13.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.3M | $-16.7M |
| Free Cash FlowOCF − Capex | $-37.5M | $-16.7M |
| FCF MarginFCF / Revenue | -4480.4% | -1211.0% |
| Capex IntensityCapex / Revenue | 34.6% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-167.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-37.3M | — | ||
| Q3 25 | $-35.0M | $-16.7M | ||
| Q2 25 | $-41.4M | $-1.8M | ||
| Q1 25 | $-48.9M | $-4.0M | ||
| Q4 24 | $16.2M | $3.7M | ||
| Q3 24 | — | $2.0M | ||
| Q2 24 | $-45.5M | $-864.6K | ||
| Q1 24 | $-67.7M | $-2.4M |
| Q4 25 | $-37.5M | — | ||
| Q3 25 | $-35.3M | $-16.7M | ||
| Q2 25 | $-43.0M | — | ||
| Q1 25 | $-51.3M | — | ||
| Q4 24 | $14.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-47.4M | — | ||
| Q1 24 | $-70.0M | — |
| Q4 25 | -4480.4% | — | ||
| Q3 25 | -2880.5% | -1211.0% | ||
| Q2 25 | -3855.1% | — | ||
| Q1 25 | -3526.8% | — | ||
| Q4 24 | 662.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -11849.6% | — |
| Q4 25 | 34.6% | — | ||
| Q3 25 | 20.2% | 0.0% | ||
| Q2 25 | 141.0% | — | ||
| Q1 25 | 166.6% | — | ||
| Q4 24 | 82.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 393.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -3.70× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
